Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In the last decades, numerous publications have broken the old paradigm that considered the urogenital tracts as sterile, demonstrating that microorganisms present in the urogenital tract represent the 9% of the whole human microbiome. Healthy urogenital microbiome improves implantation rate and pregnancy outcomes, whereas 40% of dysbiosis prevalence is observed in women under assisted reproductive treatment (ART).
Infertility causes are associated with male, female, or combined failure. It has been shown that oral probiotic treatment, mainly with Lactobacillus, recovers a healthy vaginal microbiota without safety concerns.
An interventional, randomized, double-blind, placebo-controlled study will be conducted to confirm the positive effect of the commercial probiotic product Fertibiome® on the vaginal dysbiosis of couples or women with fertility disorders.
The duration of the study will be of 6 months approximately, including 6 months of product intake. In case of pregnancy during intervention, women will continue their participation until week 12 of gestation.
Participants will be randomly assigned to one of the two study groups: control group with placebo administration or probiotic administration group. Women will take 1 capsule every 12 hours and men 1 per day. In case of women participating alone they will take 1 capsule every 12 hours. In case of pregnancy, only women will continue taking 1 capsule per day for the first 12 weeks.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Probiotic | Active Comparator | Women will take two daily doses containing approximately 2*10E9 Colony Forming Unit (CFU) of Ligilactobacillus salivarius PS11610 (Fertibiome®). Men will take one daily dose containing approximately 1*10E9 CFU of Ligilactobacillus salivarius PS11610 (Fertibiome®). In case of pregnancy during intervention, only women will continue taking 1 daily dose for the first 12 weeks of gestation. |
|
| Placebo | Placebo Comparator | Women will take two daily doses of Placebo supplement. Men will take one daily dose of Placebo supplement. In case of pregnancy during intervention, only women will continue taking 1 daily dose for the first 12 weeks of gestation. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Probiotic | Dietary Supplement |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage (%) of women with vaginal dysbiosis after 3 months of treatment. | The percentage of vaginal dysbiosis confirmed will be compared between groups of treatment. | After 3 months of intervention. |
| Percentage (%) of women with vaginal dysbiosis after 6 months of treatment. | The percentage of vaginal dysbiosis confirmed will be compared between groups of treatment. | After 6 months of intervention. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of vaginal dysbiosis criteria in case of pregnancy confirmation. | Up to 6 months. | |
| Percentage (%) of women with vaginal dysbiosis. | Before intervention. | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Women, not participating in the study with a couple, who have not undergone at least 4 cycles of artificial insemination with donor's sperm (AID) or 1 cycle of IVF without achieving evolutionary pregnancy.
Women with Body Mass Index (BMI) ≥ 30.
Couples where the woman has not infertility diagnosis while the man has any of the following characteristics:
Couples or women with any of the following characteristics:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Susana Manzano Jiménez, PhD | Contact | 918035179 | susana.manzano@probisearch.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dr. Miguel Raimundo (Portugal) | Recruiting | Lisbon | Portugal |
Not provided
| ID | Term |
|---|---|
| D019936 | Probiotics |
| ID | Term |
|---|---|
| D019587 | Dietary Supplements |
| D005502 | Food |
| D000066888 | Diet, Food, and Nutrition |
| D010829 | Physiological Phenomena |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Placebo | Dietary Supplement |
|
|
| Number of dysbiosis criteria per woman. |
| Before intervention. |
| Number of dysbiosis criteria per woman. | After 3 months of treatment pregnancy confirmation. |
| Number of dysbiosis criteria per woman. | After 6 months of treatment or pregnancy confirmation. |
| Percentage of Lactobacillus in vaginal microbiota. | Before intervention. |
| Percentage of Lactobacillus in vaginal microbiota. | After 3 months of treatment or pregnancy confirmation. |
| Percentage of Lactobacillus in vaginal microbiota. | After 6 months of treatment or pregnancy confirmation. |
| Number of reproductive treatments during the study period. | After 6 months of treatment or pregnancy confirmation. |
| Pregnancy rate. | After 6 months of treatment or pregnancy confirmation. |
| Time elapsed from the beginning of the study, until the occurrence of pregnancy. | Up to 6 months. |
| Spontaneous pregnancy rate, not associated to fertility treatment (IVF or AI). | Up to 6 months. |
| Miscarriage rate in the first trimester of pregnancy. | Before 12 weeks of pregnancy. |
| Number of oocytes extracted. | Before IVF cycle. |
| Embryo Quality (A, B or C). | Before IVF cycle. |
| Number of vaginal dysbiosis criteria at the time of embryo transfer per IVF cycle. | Before IVF cycle. |
| Levels (pg/ml) of pro-inflammatory and anti-inflammatory markers in blood plasma of women. | Before intervention. |
| Levels (pg/ml) of pro-inflammatory and anti-inflammatory markers in blood plasma of women. | After 6 months of treatment or pregnancy confirmation. |
| Hospital Universitario La Paz | Recruiting | Madrid | Madrid | 28046 | Spain |
|
| D019602 |
| Food and Beverages |